Luteolin diglucuronide significantly reduced mean arterial pressure by 21.6% (152 vs 184 mm Hg) and increased the parasympathetic component of baroreflex sensitivity in a rat model of renovascular hypertension.
Does luteolin diglucuronide improve mean arterial pressure, baroreflex sensitivity, and cardiorenal remodeling in a 1K-1C rat model of renovascular hypertension?
Luteolin diglucuronide exerts beneficial antihypertensive, cardio- and renoprotective effects in a rat model of renovascular hypertension by improving baroreflex sensitivity and reducing sterile inflammation.
Mean Difference: -32
Absolute Event Rate: 152% vs 184%
p-value: p=<0.01
Background. This study aimed to examine the pharmacodynamic efficacy of the natural flavonoid com- pound luteolin diglucuronide (Lut) in preventing disturbances in baroreflex sensitivity (BRS) and reno- and cardiovascular hypertrophy in a one-kidney, one-clip (1K-1C) model of renovascular hypertension (RVH). Material and methods. Male Wistar rats, 3 months of age, were randomized into three groups: sham- -operated (SO) (n = 17); 1K-1C (subjected to renal artery clipping to induce renovascular hyperten- sion, n = 22); and 1K-1C treated with Lut (n = 23). Rats with RVH were treated with Lut 3 mg/kg/day for 2 weeks after the first week of surgical intervention. The pharmacological efficacy of Lut on mean arterial pressure (MAP), heart rate (HR), BRS, and cardiac and kidney remodeling was evaluated. ELISA kits were used to determine total epoxyeicosatrienoic acids (EETs), prostaglandin E2 (PGE2), proinflam- matory cytokines, blood urea nitrogen (BUN), and the plasma norepinephrine (NE)/epinephrine (EPN) ratio. Results. Preventive, long-term treatment with Lut 3 mg/kg intraperitoneally ( i.p .) daily in RVH rats significantly reduced MAP by 21% and increased the parasympathetic component of BRS by 34.4%, without marked alteration in the sympathetic component. Such deremodeling in BRS was associated with a significant decrease in heart and kidney hypertrophy and normalization of BUN in plasma. Prolonged treatment with Lut at small doses led to an increase in total EETs, which was coupled with reductions in interleukin 1beta (IL-1β), tumor necrosis factor alpha (TNF-α), and endothelin 1 (ET1) levels. Lut attenuated the elevation of norepinephrine and epinephrine levels in plasma. Conclusions. Thus, Lut provides a preventive, beneficial, pluripotent action in the “low-renin” model of RVH by exerting antihypertensive, cardio- and renoprotective effects and decreasing the development of “sterile inflammation”.
Ghonghadze et al. (Thu,) conducted a other in Renovascular hypertension (n=62). Luteolin diglucuronide vs. Vehicle (0.1% DMSO in PBS) was evaluated on Mean arterial pressure (MAP) (21.6% reduction, p=<0.01). Luteolin diglucuronide significantly reduced mean arterial pressure by 21.6% (152 vs 184 mm Hg) and increased the parasympathetic component of baroreflex sensitivity in a rat model of renovascular hypertension.